Analisi costo-efficacia di caplacizumab nel nuovo standard of care della porpora trombotica trombocitopenica immune in Italia

OBJECTIVES: To evaluate the cost-effectiveness analysis (CEA) of caplacizumab in combination with plasmapheresis (PEX) and immunosuppression compared to PEX and immunosuppression in the treatment of acute episodes of iTTP. METHODS: A Markov model was used to conduct the CEA from the perspective of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Minno, Giovanni, Ravasio, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616191/
https://www.ncbi.nlm.nih.gov/pubmed/36627883
http://dx.doi.org/10.33393/grhta.2021.2191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616191/
https://www.ncbi.nlm.nih.gov/pubmed/36627883
http://dx.doi.org/10.33393/grhta.2021.2191

Ejemplares similares